Skip to main content

Advertisement

SpringerLink
Log in

Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction)

  • RADIOTHERAPY
  • Published:
La radiologia medica Aims and scope Submit manuscript

Abstract

Background

The prognosis of locally advanced non-small cell lung cancer (NSCLC) treated with conventional radiotherapy remains poor. Hypofractionation reduces overall treatment time increasing biological effect in patients not suitable for concurrent chemo-radiotherapy.

Method

From January 2009 to October 2016, 76 inoperable locally advanced primary or recurrent NSCLC patients were treated with 60 Gy in 20 fractions of 3 Gy/each for 4 weeks as exclusive or post-chemotherapy treatment. Fifty-eight patients (76.3%) had stage III and 18 (23.7%) stage IV (≤ 2 metastases) disease: 63 primary (82.9%) and 13 recurrent (17.1%).

Results

Median and 2-year overall survival were 17 months and 38.9%, respectively. Median and 2-year loco-regional progression free survival were 27 months and 55.3%, respectively. Univariate and multivariate analyses demonstrated that patients with complete response presented better outcomes, whereas no statistically relevant difference was evidenced in terms of previous chemotherapy, recurrent vs primary disease, volume and stage. Thirty patients (39.5%) presented acute esophagitis (1—grade 3) and 19 (25.0%) acute pneumonitis (2—grade 3). Six patients (7.9%) developed grade 2–3 late pneumonitis and 3 patients (3.9%) grade 1 late esophagitis.

Conclusion

In patients not suitable of concurrent radio-chemotherapy, exclusive or sequential hypofractionated schedule using 60 Gy in 20 fractions was well tolerated and presented promising results. Complete local response was a predictor of better outcomes, and any efforts will be made to perform prospective clinical trials to further evaluate hypofractionated regimens with increased lesional BED.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. National Cancer Institute (2012–2016) SEER cancer statistics factsheets: lung and bronchus cancer. National Cancer Institute, Bethesda. http://seer.cancer.gov/statfacts/html/lungb.html

  2. Le Pechoux C (2011) Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 16:672–681

    Article  Google Scholar 

  3. Schwarzenberger P, Fariss A, Linares L, Nedzi L, Salazar OM (2011) Dose escalation of once weekly vinorelbine concurrent with weekly split dose hypofractionated chest radiation for palliation of advanced non-small cell lung cancer: a phase I/II study. Am J Med Sci 341:454–459

    Article  Google Scholar 

  4. Jassem J (2007) The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol 83:203–213

    Article  Google Scholar 

  5. Pemberton LS, Din OS, Fisher PM, Hatton MQ (2009) Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-center retrospective study of outcome. Clin Oncol 21:161–167

    Article  CAS  Google Scholar 

  6. Matsuura K, Kimura T, Kashiwado K, Fujita K, Akagi Y, Yuki S, Murakami Y, Wadasaki K, Monzen Y, Ito A, Kagemoto M, Mori M, Ito K, Nagata Y (2009) Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer. Int J Clin Oncol 14:408–415

    Article  CAS  Google Scholar 

  7. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199

    Article  CAS  Google Scholar 

  8. Fowler JF, Chappell R (2000) Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 46:516–517

    Article  CAS  Google Scholar 

  9. Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J (2001) A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 49:23–33

    Article  CAS  Google Scholar 

  10. Valeriani M, Marinelli L, Reverberi C, De Sanctis V, Mollo D, Nicosia L, Osti MF (2019) Inoperable early-stage primary and early recurrent non-small cell lung cancer: outcomes of a mono-institutional experience using a moderate hypofractionated schedule. Radiol Med 124(1):58–64

    Article  Google Scholar 

  11. Zhu ZF, Fan M, Wu KL, Zhao KL, Yang HJ, Chrn GY, Jiang GL, Wang LJ, Zhao S, Fu XL (2011) A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiother Oncol 98:304–308

    Article  Google Scholar 

  12. Osti MF, Agolli L, Valeriani M, Falco T, Bracci S, De Sanctis V, Maurizi Enrici R (2013) Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiation Oncol Biol Phys 85(3):e157–e163

    Article  Google Scholar 

  13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyter S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  Google Scholar 

  14. Kaster TS, Yaremko B, Palma DA, Rodrigues GB (2015) Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clin Lung Cancer 16(2):71–79

    Article  Google Scholar 

  15. Graham MV, Pajak TE, Herskovic AM, Emami B, Perez CA (1995) Phase I/II study of treatment of locally advanced (T3/T4) noneoat cell lung cancer with concomitant boost radiotherapy by the radiation therapy oncology group (RTOG 83-12): long-term results. Int J Radiat Oncol Biol Phys 31:819–825

    Article  CAS  Google Scholar 

  16. Nguyen LN, Komaki R, Allen P, Schea RA, Milas L (1999) Effectiveness of accelerated radiotherapy for patients with inoperable nonesmall cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review. Int J Radiat Oncol Biol Phys 44:1053–1056

    Article  CAS  Google Scholar 

  17. Holloway CL, Robinson D, Murray B, Amanie J, Butts C, Smylie M, Chu K, McEwan AJ, Halperin R, Roa WH (2004) Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with nonesmall cell lung cancer. Radiother Oncol 73:285–287

    Article  Google Scholar 

  18. McPartlin AJ, Chaudhry S, Swindell R, Bayman P, Burt P, Chittalia A, Cootes J, Faivre Finn C, Harris M, Lander H, Lee L, Sheikh H, Pemberton L (2013) The largest UK single centre series using hypofractionated radical radiotherapy for NSCLC in the very elderly. Lung Cancer 81:144

    Article  CAS  Google Scholar 

  19. Din OS, Harden SV, Hudson E, Mohammed N, Pemberton SL, Lester JF, Biswas D, Magee L, Tufail A, Carruthers R, Sheikh GD, Hatton MQF (2013) Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. Radiother Oncol 109:8–12

    Article  Google Scholar 

  20. Jaksic N, Chajon E, Bellec J, Corre R, Ricordel C, de Latour B, Lena H, Schick U, de Crevoisier R, Castelli J (2018) Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer. Radiat Oncol 13(1):147

    Article  Google Scholar 

  21. Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR (2015) Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer 16:156–163

    Article  Google Scholar 

  22. Fondevilla Soler A, López-Guerra JL, Dzugashvili M, Sempere Rincón P, Sautbaet A, Castañeda P, Díaz JM, Praena-Fernandez JM, del Campo ER, Azinovic I (2017) Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced nonsmall cell lung cancer patients. Clin Transl Oncol 19(12):1469–1477. https://doi.org/10.1007/s12094-017-1689-z

    Article  CAS  PubMed  Google Scholar 

  23. Ji K, Zhao LJ, Liu WS, Liu ZY, Yuan ZY, Pang QS, Wang J, Wang P (2014) Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study. Br J Radiol 87:20130562

    Article  CAS  Google Scholar 

  24. Xu Y, Zheng X, Bai X, Li P, Ma H, Wang J, Hu X, Chen M (2017) Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: a retrospective study. Oncotarget 8(30):49084–49092

    Article  Google Scholar 

  25. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C (2007) Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43(1):114–121

    Article  Google Scholar 

  26. Maguire J, Khan I, McMenemin R, Rourke ON, McNee S, Kelly V, Peedel C, Snee M (2014) SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radicalhypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer 50:2939–2949

    Article  CAS  Google Scholar 

  27. Cho KH, Ahn SJ, Pyo HR, Kim K-S, Kum Y-C, Moon SH, Han JY, Kim HT, Koom WS, Lee JS (2009) A phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable non-small-cell lung cancer: results of Korean radiation oncology group 0301 study. Int J Radiat Oncol Biol Phys 74:1397–1404

    Article  Google Scholar 

  28. Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM (2013) Dose-limiting toxicity after hypofractionated dose escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol 31(34):4343–4348

    Article  Google Scholar 

  29. Machtay M, Swann S, Komaki R, Albain K, Sause WT, Curran WJ (2005) Higher BED is associated with improved local-regional control and survival for NSCLC treated with chemoradiotherapy: an RTOG analysis. Int J Radiat Oncol Biol Phys 63(Suppl):S40

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Sant’ Andrea Hospital, “Sapienza” University, Via di Grottarossa 1035-1039, 00189, Rome, Italy

    Maurizio Valeriani, Luca Marinelli, Luca Nicosia, Chiara Reverberi, Vitaliana De Sanctis, Davide Mollo & Mattia Falchetto Osti

Authors
  1. Maurizio Valeriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Marinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luca Nicosia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiara Reverberi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vitaliana De Sanctis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Davide Mollo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mattia Falchetto Osti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurizio Valeriani.

Ethics declarations

Conflict of interest

All authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Valeriani, M., Marinelli, L., Nicosia, L. et al. Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction). Radiol med 124, 1324–1332 (2019). https://doi.org/10.1007/s11547-019-01064-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11547-019-01064-2

Keywords

Search

Navigation